Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cree (CREE) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster citing valuation. 2. Goldman Sachs (GS) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier saying the uncertainty around the 1MDB investigation could limit the stock's upside potential if markets stabilize. 3. Denbury Resources (DNR) downgraded to Perform from Outperform at Oppenheimer with analyst Tim Rezvan saying he lacks confidence that Denbury will get enough votes to close the acquisition of Penn Virginia (PVAC) and sees an increased risk of "strategic limbo" should the deal fall through. 4. Sprouts Farmers Market (SFM) downgraded to Underperform from Buy at BofA/Merrill with analyst Robert Ohems following CEO Amin Maredla's plans to leave the company. Ohems believes Maredla is leaving to pursue other interests, but said the transition comes at a difficult time given expectations Q4 and 1H 2019 are already expected to be challenging. 5. Assertio Therapeutics (ASRT) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying while the amended Nucynta royalty agreement with Collegium removes an overhang on the stock, the stock's one-year upside is limited. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.